Klaus Binder

Klaus Binder is a life science industry leader with more than 25 years of experience combining an understanding of therapeutic product development, technologies and corporate development with an excellent international network. He was the founding CEO of CEVEC Pharmaceuticals and served on the board of several companies including Amaxa, Natrix Separations and Pfanstiehl Corporation. Since 2000, he independently advises biotech, pharma and life science companies with a focus on pre-clinical development, manufacturing and corporate strategies including M&A.

Klaus started his career at Boehringer Ingelheim (BI) in 1990 where he gained in-depth experience in drug discovery and pre-clinical development. Following he held positions in Business Development & Strategic Marketing and became part of the management of the BI Biopharmaceutical Contract Manufacturing business unit as Head of Corporate Business Development & Marketing where he was responsible for the successful contract acquisition and world-wide branding of manufacturing sites in Biberach, Germany, and Vienna, Austria. Klaus holds a PhD in Biology from the University Ulm, Germany.